CTRI/2024/05/067778
Not yet recruiting
Phase 3
A prospective, open label, single centre study for evaluation of efficacy and safety of Appelite Syrup in the management of Dyspepsia (Indigestion),Loss of Appetite And Acidity - NI
Healing Hands & Herbs Pvt. Ltd.0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Healing Hands & Herbs Pvt. Ltd.
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients aged above 18 years of age. 2\.Patient with a diagnosis of Dyspepsia (indigestion) or loss of appetite or acidity. 3\.Patient or Parent or legal guardian willing to give a written informed consent or parental consent or assent form. 4\.Able to or Willing to strictly adhere to the investigator’s prescription.
Exclusion Criteria
- •1\.Individuals were excluded if they had taken any medications that might interfere with the action of the study medications prior to the start of the study or during the study.
- •2\.Patients with a medical history and diagnosis of Diabetes were excluded from the study.
- •3\.Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to investigate the effect of riociguat on right heart size and function in pulmonary hypertensioSymptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance =2 Wood Units, pulmonary arterial wedge pressure =15 mmHg (Group I / Nice Clinical Classification of Pulmonary Hypertension (PH)) or CTEPH (Group IV) with hemodynamics as stated above defined as inoperable measured at least 3 months after start of full anticoagulation or with persisting or recurrent PH after pulmonary endarterectomy at least 6 months after surgeryMedDRA version: 20.0Level: HLTClassification code 10037401Term: Pulmonary hypertensionsSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-005462-34-DEThoraxklinik Heidelberg gGmbH30
Active, not recruiting
Phase 1
An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary HypertensioPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary HypertensionMedDRA version: 20.0Level: HLTClassification code: 10037401Term: Pulmonary hypertensions Class: 10047065Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2023-509696-17-00Thoraxklinik Heidelberg gGmbH30
Not yet recruiting
Not Applicable
Open label study for Evaluation of glycemic index (GI) of Diabliss Herbal Sugar for food classification per ISO 26642 test procedure among healthy subjectsCTRI/2024/07/070733Diabliss Consumer Products Pvt Limited
Completed
Not Applicable
Single center, open-label study investigating the excretion balance, pharmacokinetics and metabolism of a single oral dose of [14C]-labeled RO6889450 in healthy male volunteersSchizophrenia10039628NL-OMON51079F. Hoffman-La Roche Ltd6
Not yet recruiting
Not Applicable
A single-center, prospective, open-label study investigating the effect of Ninjin'yoeito on frailty in hemodialysis patients.frailty in hemodialysis patientsJPRN-UMIN000052058Japanese Red Cross Kumamoto Hospital40